May 6, 2011, Saint Louis Business Journal

Local biotech startup C2N Diagnostics LLC is leading the way in finding new, more effective treatments for Alzheimer’s disease and other disorders through a unique metabolic labeling technology.

The technology, stable isotope-linked kinetics (SILK), was discovered at Washington University School of Medicine by Drs. Randall Bateman and David Holtzman. The technique allows tracking of the brain’s production and clearance of amyloid beta, a protein that’s closely linked to the disease. This gives scientists insights into the progression of the disease and enables physicians to start an effective course of treatment before the patient exhibits clinical symptoms.

Read more: C2N tracking technology finds Alzheimer's faster | St. Louis Business Journal

April 1, 2011, Healthcare Digital

A new series from HEC-TV showcases the role of C2N's technology in exploring questions about the origins of Alzheimer's Disease

C2N is an emerging biomarkers company out of the St. Louis region. The company serves as a good example of the contributions that start-up companies can provide to society based on important technologies developed within the laboratories of academic centers.

The Link below is an innovations program that the Higher Education Channel out of St. Louis just recently televised.

http://www.hectv.org/programs/ser/innovations/ep297.php

The fourth segment of the show (beginning at 20 mins 35 secs) covers Dr. Randall Bateman's (one of C2N's two scientific co-founders) Alzheimer's research work at Washington University, along with work that is ongoing at C2N. C2N is commercializing a suite of biomarkers that intend to speed the development of therapeutics and diagnostics for serious disorders affecting the central nervous system and cognition.

C2N Diagnostics co-founding scientist – Dr. Randall Bateman – and colleagues at Washington University School of Medicine publish key findings in online edition of Science

ST. LOUIS, MO – C2N Diagnostics announced today that one of its co-founding scientists, Dr. Randall Bateman, and his colleagues from the Washington University School of Medicine have independently authored an article that appeared in yesterday’s online edition of Science. The publication, entitled “Decreased Clearance of CNS Amyloid-b in Alzheimer’s Disease”, sheds important new light into the potential origins of late-onset, or sporadic, Alzheimer’s Disease (AD). The findings may also aid in the future development of an early diagnostic test and target for effective drug therapy.

April 21, 2010, St. Louis Post Dispatch

From St. Louis Post Dispatch:

Another local startup, C2N Diagnostics, is working with pharmaceutical companies to develop a test that can detect Alzheimer's at its earliest stages and also to guide effective treatment before patients manifest clinical symptoms. By the time symptoms are observed, neurological damage has occurred. So the goal is to catch Alzheimer's early — to delay or prevent symptoms in someone who has a high risk of developing it in the future.

"We need better measurements and tools to both discover drugs for Alzheimer's as well as to develop them clinically," said Joel Braunstein, a co-founder of C2N.

Cutting health care costs is just one of the messages pitched by medical entrepreneurs to investors.

Read more